Lily Hwang, MD
Allergy & Immunology · Roswell, GANPI 1669648986
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,505 of the $88,499 with a category attached, or 67.2%. 39 manufacturers reported payments, led by AstraZeneca at 50.5% of the total. Among allergy & immunology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $153.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$45K
- Pfizer$22K
- Novartis$7K
- Genentech, Inc.$4K
- Grifols USA, LLC$3K
- GSK$1K
- plus $7K from 33 others
What the payments were for
- Consulting fees$10,77912%
- Speaking & faculty fees$59,50567%
- Travel & lodging$4,2575%
- Food & beverage$13,74316%
- Education$2160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $44,651 |
| Pfizer | 68 | $22,225 |
| Novartis | 42 | $6,644 |
| Genentech, Inc. | 2 | $4,155 |
| Grifols USA, LLC | 16 | $2,704 |
| GSK | 66 | $1,362 |
| Sanofi | 42 | $1,246 |
| Regeneron Healthcare Solutions, Inc. | 26 | $722 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $689 |
| Amgen(2 entities) | 30 | $613 |
| CSL Behring | 17 | $429 |
| Covis Pharma GmbH | 21 | $405 |
| Genentech USA, Inc. | 12 | $345 |
| Teva Pharmaceuticals USA, Inc. | 14 | $310 |
| Biocryst US Sales Co., LLC | 13 | $304 |
| Pharming Healthcare, Inc. | 8 | $199 |
| Sanofi-aventis U.S. LLC | 2 | $197 |
| Boehringer Ingelheim | 8 | $192 |
| Kaleo, Inc. | 7 | $151 |
| Blueprint Medicines Corporation | 2 | $132 |
| Optinose US, Inc. | 6 | $107 |
| Dermavant Sciences, Inc. | 1 | $96 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $76 |
| AbbVie | 3 | $67 |
| Octapharma USA, Inc. | 1 | $64 |
| Shire North American Group Inc | 4 | $61 |
| Jubilant Hollisterstier LLC | 1 | $57 |
| ADMA Biomanufacturing LLC | 2 | $44 |
| Alk-abello, Inc | 2 | $36 |
| LEO Pharma Inc. | 1 | $35 |
| Organon | 1 | $25 |
| Medline Industries LP | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Merck | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Incyte Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,499 in reported general payments places this provider in the 90th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $132,816 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $91,439 |
| Dupixent SyringeDupilumab | 18 | $67,832 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $67,112 |
| HyqviaIgg/Hyaluronidase,recombinant | 22 | $58,552 |
| TezspireTezepelumab-Ekko | 14 | $56,490 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $54,886 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 253 | $53,324 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 157 | $45,641 |
| Dupixent PenDupilumab | 11 | $45,251 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 123 | $37,970 |
| MresviaRsv Vaccine, Pref, Mrna/Pf | 78 | $24,116 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $18,668 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $15,552 |
| Cromolyn Sodium | 13 | $9,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta, Arnuity Ellipta | $1,362 | $189,194532 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Hyqvia | $689 | $149,99144 claims |
| CSL BehringHizentra | $429 | $132,81618 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $44,651 | $81,48057 claims |
| Grifols USA, LLCGamunex-C | $2,704 | $54,88612 claims |
| PfizerAbrysvo | $22,225 | $37,970123 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $8,47946 claims |
| Boehringer IngelheimSpiriva Respimat | $192 | $6,92211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Roswell
- Michael BlaissRoswell$1.1M
- Meera PatrawalaRoswell$12K
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Paul RabinowitzAtlanta$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.